U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–FDA filing acceptance announced for Enspryng (satralizumab) in MOGAD, a rare neurological disease.